Education
About Us
Working with TipRanks
Follow Us
Cyclerion Therapeutics,Inc. (CYCN)
:CYCN
CYCN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.27 - $9.47
Previous CloseN/A
Volume28.13K
Average Volume (3M)49.58K
Market Cap
$8.48M
Enterprise Value$2.28M
Total Cash (Recent Filing)$3.01M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.47
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding3,337,436
10 Day Avg. Volume32,144
30 Day Avg. Volume49,575
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue1.05
Enterprise Value/Gross Profit1.10
Enterprise Value/Ebitda-0.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cyclerion Therapeutics News
CYCN FAQ
What was Cyclerion Therapeutics,Inc.’s price range in the past 12 months?
Cyclerion Therapeutics,Inc. lowest stock price was $1.27 and its highest was $9.47 in the past 12 months.
What is Cyclerion Therapeutics,Inc.’s market cap?
Cyclerion Therapeutics,Inc.’s market cap is $8.48M.
When is Cyclerion Therapeutics,Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cyclerion Therapeutics,Inc.’s earnings last quarter?
Currently, no data Available
Is Cyclerion Therapeutics,Inc. overvalued?
According to Wall Street analysts Cyclerion Therapeutics,Inc.’s price is currently Overvalued.
Does Cyclerion Therapeutics,Inc. pay dividends?
Cyclerion Therapeutics,Inc. does not currently pay dividends.
What is Cyclerion Therapeutics,Inc.’s EPS estimate?
Cyclerion Therapeutics,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclerion Therapeutics,Inc. have?
Cyclerion Therapeutics,Inc. has 3,337,436 shares outstanding.
What happened to Cyclerion Therapeutics,Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cyclerion Therapeutics,Inc.?
Currently, no hedge funds are holding shares in CYCN
Company Description
Cyclerion Therapeutics,Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics (CYCN) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Carisma Therapeutics
―
Aprea Therapeutics
―
Evaxion Biotech
―
HCW Biologics
―
Turnstone Biologics Corp.
―
Ownership Overview
17.68% Insiders
1.21% Mutual Funds
8.13% Other Institutional Investors
72.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---